

Product datasheet for **TR502627**

Pla2g10 Mouse shRNA Plasmid (Locus ID 26565)

Product data:

| | |
|---------------------------|---|
| Product Type: | shRNA Plasmids |
| Product Name: | Pla2g10 Mouse shRNA Plasmid (Locus ID 26565) |
| Locus ID: | 26565 |
| Synonyms: | GX sPLA2; mGXs; PLA; PLA2GX; sPLA2-X |
| Vector: | pRS (TR20003) |
| E. coli Selection: | Ampicillin |
| Mammalian Cell Selection: | Puromycin |
| Format: | Retroviral plasmids |
| Components: | Pla2g10 - Mouse, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID = 26565). 5µg purified plasmid DNA per construct 29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free. |
| RefSeq: | BC028879 , NM_001291009 , NM_011987 , NR_110990 , NM_011987.1 , NM_011987.2 , NM_011987.3 , NM_011987.4 , NM_001291009.1 , NM_001291009.2 |
| UniProt ID: | Q9QXX3 |
| Summary: | This gene encodes a member of the phospholipase A2 family of lipolytic enzymes that hydrolyzes glycerophospholipids to produce free fatty acids and lysophospholipids. The encoded protein undergoes proteolytic processing to generate a calcium-dependent enzyme that plays pivotal roles in the liberation of arachidonic acid from membrane phospholipids leading to the production of various inflammatory lipid mediators, such as prostaglandins. In response to myocardial ischemia/reperfusion, mice lacking the encoded protein display a reduction in myocardial infarct size partly through the suppression of neutrophil cytotoxic activities. Alternative splicing results in multiple transcript variants encoding different isoforms. All of these isoforms may undergo similar processing to generate the mature protein. [provided by RefSeq, Jul 2015] |
| shRNA Design: | These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com . If you need a special design or shRNA sequence, please utilize our custom shRNA service . |



[View online »](#)

**Performance
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).